

C. RICHARD DANIEL, M. D.

P. O. BOX 888

BECKLEY, WEST VIRGINIA 25801

25 Feb 87

Nuclear Regulatory Commission  
Washington, D.C. 20555

Gentlemen:


In applying for approval for interpretation of nuclear scans from the Dag Hammarskjold Cancer Treatment Center, 205 Dry Hill Road, Box 2286, Beckley, W. Va. 25801, I am enclosing the following pertinent data:

1. A copy of my original application as Chief of Radiology, Raleigh General Hospital, Beckley, W. Va. detailing my training in Nuclear Medicine at Philadelphia General Hospital, Philadelphia, Pa. I have since resigned my post at Raleigh General.

2. A listing of nuclear medicine scans personally supervised and interpreted at Raleigh General from early 1978 to September 1, 1982.

Thank you for your help.

Sincerely,



C. Richard Daniel, M.D.  
Chief of Radiology  
Beckley Hospital and  
Beckley Medical Arts

8801270360 870729  
REG2 LIC30  
47-24832-01 PDR

TRAINING AND EXPERIENCE  
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

*C. RICHARD DANIEL, M.D.*

2. STATE OR TERRITORY IN  
WHICH LICENSED TO  
PRACTICE MEDICINE

*W.VA.*

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
<i>RADIOLOGY</i>	<i>DIAGNOSTIC RADIOLOGY, THERAPEUTIC RADIOLOGY (RADIATION THERAPY), AND NUCLEAR MEDICINE.</i>	<i>JUNE, 1964</i>

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION	<i>PHILADELPHIA GEN. HOSPITAL PHILADELPHIA, PA.</i>	<i>100</i>	<i>100</i>
b. RADIATION PROTECTION	<i>"</i>	<i>30</i>	<i>30</i>
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	<i>"</i>	<i>20</i>	<i>20</i>
d. RADIATION BIOLOGY	<i>"</i>	<i>20</i>	<i>20</i>
e. RADIOPHARMACEUTICAL CHEMISTRY	<i>"</i>	<i>30</i>	<i>30</i>

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
		<i>SEE ATTACHED FORM.</i>		

UNITED STATES ATOMIC ENERGY COMMISSION  
**APPLICATION FOR BYPRODUCT MATERIAL LICENSE—MEDICAL**  
SUPPLEMENT A—PRECEPTOR STATEMENT

This page is to be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each. Page 2 may be used for comments and additional information.

10. NAME AND ADDRESS OF APPLICANT PHYSICIAN (Include ZIP Code.)

C. Richard Daniel, M.D.  
Raleigh General Hospital  
Beckley, West Virginia 25801

11. CLINICAL TRAINING AND EXPERIENCE OF PHYSICIAN NAMED IN ITEM 10 ABOVE

(A) ISOTOPE	(B) CONDITIONS DIAGNOSED OR TREATED	(C) No. Cases Observed (See 1 in key below)	(D) No. Cases Involving Personal Participation (See 2 in key below)
I-131 or I-125	Diagnosis of thyroid function	54	35
	Determination of blood and blood plasma volume	30	21
	Liver function studies	5	3
	Fat absorption studies		
	Kidney function studies		
	In vitro studies		
Cr-51	Gastrointestinal protein loss studies		
	Determination of red blood cell volume and studies of red blood cell survival	12	5
Fe-59	Iron turn over studies	1	1
Co-58 or Co-60	Intestinal absorption studies	7	5
K-42	Potassium space determinations		
I-131	Thyroid imaging	70	41
	Brain tumor localization and cardiac imaging	4	2
	Cisternography		
	Lung imaging		
	Liver imaging	6	3
	Kidney imaging		
	Placenta localization		
Cr-51	Placenta localization		
	Spleen imaging		
Au-198	Liver imaging		
Hg-197	Brain imaging		
	Kidney imaging		
Hg-203	Brain imaging		
Sr-85	Bone imaging		
Tc-99m	Brain imaging		
	Thyroid imaging		
	Salivary gland imaging		
	Blood pool imaging		

# APPLICATION FOR BYPRODUCT MATERIAL LICENSE—MEDICAL SUPPLEMENT A—HUMAN USE

(A) ISOTOPE	(B) CONDITIONS DIAGNOSED OR TREATED	(C) No. Cases Observed (See 1 in key below)	(D) No. Cases Involving Personal Participation (See 2 in key below)
Tc-99m	Placenta localization		
	Liver and spleen imaging		
	Lung imaging		
	Bone imaging		
Xe-133	Blood flow studies and pulmonary function studies		
Se-75	Pancreas imaging		
P-32	Treatment of polycythemia, leukemia, and Bone metastases	4	3
	Intracavitary treatment	2	2
I-131	Treatment of thyroid carcinoma	2	2
	Treatment of hyperthyroidism and cardiac condition	4	3
Au-198	Intracavitary treatment	3	2
Co-60 or <del>Co-60</del>	Interstitial treatment & Ra-226	4	2
	Intracavitary treatment & Ra-226	7	5
Ir-192	Interstitial treatment		
Co-60 CO-137	Teletherapy treatment 37-01759-08	58	36
Sr-90	Treatment of eye disease	2	2

## Key to Column (C) and (D) above

1. Observation should consist of observing radioisotope administration techniques and discussion with preceptor the case histories to establish most appropriate diagnostic and/or therapeutic procedure, limitation, contraindications, etc.
2. Personal participation should consist of (a) supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation on dosage to be prescribed; (b) collaboration in calibration of the dose and the actual administration of the dose to the patient, including calculation of the radiation dose, related measurements, and plotting of data; and (c) adequate period of training to enable the physician to manage radioactive patients and to follow patients through diagnosis and/or the course of treatment.

12. DATES AND TOTAL NUMBER OF HOURS OF CLINICAL RADIOISOTOPE TRAINING Aug., Sept., '62 - Feb. - Apr., '63

Approx. 700 hours

13. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF William Serber, M.D.


COPY

AT Phila. Gen. Hospital

(Institution) Name and Address

37-01759-01

(Byproduct Material License Number)



(Signature of Preceptor)

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS		<b>KEY TO COLUMN C</b> <b>PERSONAL PARTICIPATION SHOULD CONSIST OF:</b> 1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage. 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data. 3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.
FULL NAME <i>C. RICHARD DANIEL, M.D.</i>		
STREET ADDRESS <i>216 GRANVILLE AVE.</i>		
CITY <i>BECKLEY</i>	STATE <i>W.VA.</i>	

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION	75	PROCEDURES IN LEFT COLUMN ARE THOSE PERFORMED AT RALEIGH GENERAL HOSPITAL, BECKLEY, W.VA. 25801 FROM EARLY 1978 TO SEPTEMBER 1, 1982.
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES	18	
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING	2	
P-32	EYE TUMOR LOCALIZATION		
Se-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	372	THE RADIATION THERAPIES ON THE REVERSE OF THIS SHEET ARE THOSE DONE AT PHILADELPHIA GEN. HOSPITAL FROM 1961-63, AND ARE LISTED ON THE COPY OF THE ORIGINAL APPLICATION.
OTHER	GALLIUM SCANS	6	
Tc-99m	BRAIN IMAGING	549	
	CARDIAC IMAGING		
	THYROID IMAGING	206	
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING	354	
	LUNG IMAGING	627	
	BONE IMAGING	267	
OTHER	TESTICULAR IMAGING	2	



# PRECEPTOR STATEMENT (Continued)

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.)
A	B	C	D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	3	
P-32 (Colloidal)	INTRACAVITARY TREATMENT	2	
I-131	TREATMENT OF THYROID CARCINOMA	2	
	TREATMENT OF HYPERHYROIDISM	3	
Au-198	INTRACAVITARY TREATMENT	2	
Co-60 or Cs-137	INTERSTITIAL TREATMENT	2	
	INTRACAVITARY TREATMENT	5	
I-125 or Ir-192	INTERSTITIAL TREATMENT	0	
	TELE THERAPY TREATMENT	36	
Sr-90	TREATMENT OF EYE DISEASE	2	
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

## 3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

## 4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR

WILLIAM SERBER, M.D.

b. NAME OF INSTITUTION

PHILADELPHIA GENERAL HOSPITAL

c. MAILING ADDRESS

PHILADELPHIA, PA.

d. CITY

## 5. PRECEPTOR'S SIGNATURE

WILLIAM SERBER, M.D.

7. PRECEPTOR'S NAME (Please type or print)

(SEE ATTACHED COPY)

8. DATE

2-23-87

5. MATERIALS LICENSE NUMBER(S)

37-01759-C1